北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (4): 667-671. doi: 10.3969/j.issn.1671-167X.2016.04.020

• 论著 • 上一篇    下一篇

趋化因子配体19在类风湿关节炎患者血清中的表达及临床意义

石连杰1,李建红2,胡凡磊1,李敏3,张杰4,李江涛4,栗占国1△   

  1. (1. 北京大学人民医院风湿免疫科, 北京100044; 2. 四川大学华西医院核医学科, 成都610041; 3. 四川省骨科医院风湿科, 成都610041; 4. 宜宾市第一医院风湿科, 四川宜宾644000)
  • 出版日期:2016-08-18 发布日期:2016-08-18
  • 通讯作者: 栗占国 E-mail:zgli99@aliyun.com

Clinical significance of serum C-C chemokine ligand 19 levels in patients with rheumatoid arthritis

SHI Lian-jie1, LI Jian-hong2, HU Fan-lei1, LI Min3, ZHANG Jie4, LI Jiang-tao4, LI Zhan-guo1△   

  1. (1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China; 2. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China; 3. Department of Rheumatology, Sichuan Orthopedic Hospital, Chengdu 610041, China; 4. Department of Rheumatology, The First People’s Hospital of Yibin, Yibin 644000, Sichuan, China)
  • Online:2016-08-18 Published:2016-08-18
  • Contact: LI Zhan-guo E-mail:zgli99@aliyun.com

摘要:

目的:探讨趋化因子配体19(C-C chemokine ligand 19,CCL19)在类风湿关节炎(rheumatoid arthritis,RA)患者血清中的表达水平及临床意义。方法:采用酶联免疫吸附测定检测RA患者和健康对照血清CCL19的表达水平,收集患者临床及实验室资料,利用流式细胞术检测患者外周血B细胞及记忆B细胞亚群的比例。对比不同临床特征的RA患者血清CCL19表达差异,分析血清CCL19水平与临床及实验室指标、B细胞及记忆B细胞亚群间的相关性。数据分析采用独立样本t检验、配对t检验、Pearson和Spearman相关分析。结果:RA患者血清中高表达CCL19(P<0.001),治疗后的RA患者CCL19表达显著降低(P<0.001)。CCL19与红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reactive protein,CRP)、28个关节的疾病活动度评分(disease activity score in 28 joints,DAS28)无相关性(P>0.05),但与类风湿因子(rheumatoid factor,RF)、抗环瓜氨酸多肽(cyclic citrullinated peptide,CCP)抗体水平显著相关(r=0.42,P=0.002;r=0.33,P=0.013);CCL19水平在抗CCP抗体阳性组显著高于抗CCP抗体阴性组,RF阳性组显著高于RF阴性组,高、低疾病活动组间以及早期和非早期RA组间差异均无统计学意义;CCL19与外周血CD19+、CD27+、D27-、CD27+IgD+、CD27+IgD-、CD27-IgD+、CD27-IgD- B细胞的比例均未见显著相关性(P>0.05)。相较于健康对照,RA患者外周血CD27+IgD+、CD27+IgD-、CD27+ B细胞比例均显著减少。结论:血清CCL19水平可以反映RA患者的免疫活动状态,可预判RA患者B细胞抗体分泌的功能状态,从而可能指导RA临床治疗策略的选择。

关键词: 关节炎, 类风湿, 趋化因子CCL19, 类风湿因子, 抗体, B淋巴细胞

Abstract:

Objective:To investigate the serum level of C-C chemokine ligand 19 (CCL19) and its clinical significance in rheumatoid arthritis. Methods: The serum CCL19 levels in both rheumatoid arthritis (RA) patients and health controls were detected by ELISA. The proportion of peripheral blood B cells and memory B cell subsets were also detected in some patients. Then the clinical and laboratory data of the patients were collected. The CCL19 levels in patients with different clinical features were analyzed. And the correlation between the clinical data, laboratory parameters, B cell subsets proportion and serum CCL19 levels were also analyzed. Independent samples t test, paired t test, Pearson and Spearman correlation were used for statistical analysis. Results: The levels of CCL19 was higher in the RA patients than the health controls (P<0.05). The serum CCL19 levels were decreased in the RA patients who accep-ted disease-modifying anti-rheumatic drugs (DMARDs) treatment for 6 months (P<0.001). Serum CCL19 levels were correlated with the titers of both rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody (r=0.42, P=0.002; r=0.33, P=0.013), but not with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and disease activity score in 28 joints (DAS28) (P>0.05). The levels of CCL19 were higher in the serum positive (RF and anti-CCP antibody) patients, but there were no differences between low and high disease activity RA, as well as early and non-early RA. There was no correlation between the serum CCL19 levels and the proportion of B cells as well as memory B subsets. All the proportion of peripheral blood CD27+ memory B cell subsets in RA was lower than the healthy controls, including CD27+IgD+, CD27+IgD- and CD27+ B cells. Conclusion: The increased serum CCL19 levels in RA patients are associated with the activity of B cells, so CCL19 might predict whether the RA type is a B cell mediated RA, and specify the treatment directions for the rheumatologist.

Key words: Arthritis, rheumatoid, Chemokine CCL19, Rheumatoid factor, Antibodies, B-lymphocytes

中图分类号: 

  • R593.22
[1] 魏慧, 张警丰, 姚中强, 赵金霞. 类风湿关节炎合并慢性病贫血患者的临床特征及相关因素[J]. 北京大学学报(医学版), 2026, 58(2): 307-312.
[2] 池彦廷, 蒋鸿杰, 陈艳, 徐志秀, 李斌斌. 直接免疫荧光在口腔黏膜寻常型天疱疮诊断中的价值: 基于多指标联合分析的回顾性研究[J]. 北京大学学报(医学版), 2026, 58(1): 68-73.
[3] 练益瑞, 刘静璇, 赵亮, 赵静, 臧思田, 李玉慧. 抗PM/Scl抗体相关风湿性疾病谱及其在特发性炎性肌病中的免疫学特征[J]. 北京大学学报(医学版), 2025, 57(6): 1018-1023.
[4] 吴滔, 林建子, 朱亚锋, 马剑达, 贾霈雯, 杨莉娟, 潘婕, 邹耀威, 杨迎, 卢烨, 戴冽. 血清蛋白质谱筛选及验证类风湿关节炎患者肌肉量减少的生物标志物[J]. 北京大学学报(医学版), 2025, 57(6): 1024-1031.
[5] 林文灏, 谢阳, 王芳晴, 王淑盈, 刘香君, 胡凡磊, 贾园. 基于B细胞单细胞转录组测序的干燥综合征分子分型[J]. 北京大学学报(医学版), 2025, 57(6): 1032-1041.
[6] 王翠萍, 陈哲, 程永静. 超微血流成像评估与膝骨关节炎临床症状的关联研究[J]. 北京大学学报(医学版), 2025, 57(6): 1096-1100.
[7] 吕雪冰, 俞烜华, 张伟桢, 刘昌泉, 林互涵, 曾珊婷, 黄惠娟, 吴月萍. 类风湿关节炎合并坏死性筋膜炎1例[J]. 北京大学学报(医学版), 2025, 57(6): 1198-1202.
[8] 丁艳, 王丽芳, 李超然, 卢哲敏, 石连杰. 利妥昔单抗成功治疗类风湿关节炎合并IgG4相关性疾病1例[J]. 北京大学学报(医学版), 2025, 57(6): 1203-1207.
[9] 杨菊, 徐婧, 戴菊华, 石连杰. Lumican蛋白在类风湿关节炎患者血清中的表达及其与疾病和免疫活动的相关性[J]. 北京大学学报(医学版), 2025, 57(5): 911-918.
[10] 冯亮华, 洪丽荣, 陈雨佳, 蔡学明. 泛素特异性蛋白酶35对类风湿关节炎成纤维样滑膜细胞铁死亡的作用及机制[J]. 北京大学学报(医学版), 2025, 57(5): 919-925.
[11] 秦秋实, 李蕊, 周妍希, 张玥, 韩铭, 朱鏐娈. 敲减Blimp1基因表达对CCl4诱导的小鼠肝纤维化模型早期肝损伤的保护作用[J]. 北京大学学报(医学版), 2025, 57(4): 727-734.
[12] 贾霈雯, 杨迎, 邹耀威, 欧阳志明, 林建子, 马剑达, 杨葵敏, 戴冽. 类风湿关节炎患者低肌肉量综合征的临床特征及其对躯体功能的影响[J]. 北京大学学报(医学版), 2024, 56(6): 1009-1016.
[13] 李钰锴, 王红彦, 罗靓, 李云, 李春. 抗磷脂抗体在白塞病合并血栓中的临床意义[J]. 北京大学学报(医学版), 2024, 56(6): 1036-1040.
[14] 马豆豆, 卢哲敏, 郭倩, 朱莎, 古今, 丁艳, 石连杰. 小剂量利妥昔单抗成功治疗类风湿关节炎合并重症肌无力1例[J]. 北京大学学报(医学版), 2024, 56(6): 1110-1114.
[15] 蔡文心, 杨琼英, 韩丹, 陈哲, 程永静. 红外热成像检查在风湿病中的应用及展望[J]. 北京大学学报(医学版), 2024, 56(6): 1132-1136.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!